Science News
from research organizations

Antibody Targeting The Protein FGFR3 Inhibits Cancer Cell Growth

Date:
April 28, 2009
Source:
Journal of Clinical Investigation
Summary:
Several forms of cancer are associated with either overexpression or perpetual activation of the protein FGFR3. A new paper now provides evidence that FGFR3 might be a good therapeutic target for these cancers and describes the development of an FGFR3-targeted antibody that had potent antitumor activity in mice transplanted with human tumor cells expressing either too much or overactive FGFR3.
Share:
       
FULL STORY

Several forms of cancer, including bladder cancer and multiple myeloma caused by the t(4;14) genetic abnormality, are associated with either overexpression or perpetual activation of the protein FGFR3.

A team of researchers, at Genentech Inc., South San Francisco, has now generated evidence that FGFR3 might be a good therapeutic target for these diseases and developed an FGFR3-targeted antibody that had potent antitumor activity in mice transplanted with either human bladder cancer cells or t(4;14)-positive multiple myeloma cells.

Additional in vivo and in vitro analysis indicated that the antibody was active against normal FGFR3 and mutated forms of the protein that are associated with cancer. The authors therefore suggest that antibody targeting of FGFR3 might be a viable therapeutic approach to treating cancers associated with aberrant expression or activation of FGFR3.

In an accompanying commentary, Yaron Hadari and Joseph Schlessinger, highlight the importance of these data and suggest that they might be relevant to other diseases, as similar FGFR3 mutations have been found to cause some skeletal dysplasias, disorders that cause abnormal shape and size of the skeleton.


Story Source:

The above post is reprinted from materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Qing et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. Journal of Clinical Investigation, 2009; DOI: 10.1172/JCI38017

Cite This Page:

Journal of Clinical Investigation. "Antibody Targeting The Protein FGFR3 Inhibits Cancer Cell Growth." ScienceDaily. ScienceDaily, 28 April 2009. <www.sciencedaily.com/releases/2009/04/090420182153.htm>.
Journal of Clinical Investigation. (2009, April 28). Antibody Targeting The Protein FGFR3 Inhibits Cancer Cell Growth. ScienceDaily. Retrieved July 29, 2015 from www.sciencedaily.com/releases/2009/04/090420182153.htm
Journal of Clinical Investigation. "Antibody Targeting The Protein FGFR3 Inhibits Cancer Cell Growth." ScienceDaily. www.sciencedaily.com/releases/2009/04/090420182153.htm (accessed July 29, 2015).

Share This Page: